INTRODUCTION

Human immunodeficiency virus (HIV) disease is pandemic that has already affected 33.4 million worldwide until 2008.\(^1\) As of 2009, it was estimated that 2.4 million people were living with HIV in India alone.\(^2\) Since antiretroviral therapy (ART) have become widely and easily available and the incidence of opportunistic infections has come down. However, other systemic disorders including endocrine disorders are still not thoroughly evaluated. High incidences of different endocrine are being noted in these patients.\(^3\) Virtually every endocrine gland (adrenal, gonadal, hypothalamus-pituitary, and thyroid) has been reported to be affected in HIV patients at varying rates in different studies.\(^5,6\)

In the various ways, HIV infection directly or indirectly through opportunistic infections and/or by antiretroviral drugs can cause endocrine abnormalities. Patients not receiving ART have increased production of inflammatory cytokines due to active disease, AIDS wasting, and the presence of opportunistic infections can all contribute to development of endocrine disorders. With the initiation of treatment, immune reconstitution can precipitate autoimmune diseases such as hyperthyroidism,\(^7\) and a case of autoimmune diabetes has also been reported.\(^8\) The patient’s underlying genetic risk and environmental factors (such as over nutrition and sedentary lifestyle)
in combination with disease-related risk factors can lead to overt manifestation of latent endocrine disease.

In India, so far very few studies have conducted to understand the profile of endocrine dysfunctions in HIV patients. The present study was undertaken to understand the profile of endocrine disorders, and an effort was also made to correlate these endocrine disorders with stages of HIV disease, ART status, and body mass index (BMI) in HIV patients.

MATERIAL AND METHODS

This hospital-based observational study was done over a period of 1 year (July 2009 to June 2010) at tertiary care center of north India. HIV patients aged >15 years who gave informed consent were included. All studied patients were assessed clinically and were subjected to specific questions pertaining to endocrine disorders [Table 1]. All patients were categorized into AIDS and non-AIDS group on the basis of AIDS defining illness as per the WHO classification; ART and ART naïve; and also divided into three groups, i.e., A, B, and C on the basis of baseline CD4 counts <200 cells/mm$^3$, 200–350 cells/mm$^3$, and >350 cells/mm$^3$, respectively. Wasting in HIV patients was considered at BMI <18.5 kg/m$^2$.

Laboratory methods

The blood samples for different hormonal profile including thyroid function tests (T3, T4 and TSH), serum cortisol, serum gonadotrophins (LH and FSH), serum testosterone, serum estrogen, and serum progesterone were taken at 8:00 AM to avoid possible interference with circadian rhythms. In seriously ill patients, thyroid function test were not carried out to consider sick euthyroid syndrome. Radioimmunoassay kits were used for estimation of thyroid function tests (supplied by Board of Radiation and Isotope Technology, Mumbai) and serum cortisol, testosterone, LH, and FSH (Immunotech, Beckman Coulter, Inc., Villepinte, France).

Statistical analysis

Data were presented in mean (SD), median, interquartile, and percentage. The Mann—Whitney U test was used for comparison of two means. The comparison of two sequential measurements in the same patient was carried out using the Wilcoxon matched-pairs signed-ranks test. Categorical variables were compared with the chi square test. A stepwise logistic regression analysis was used to identify the independent association of diverse parameters with wasting in HIV disease (BMI). A $P$ value < 0.05 for a two-sided test was considered statistically significant. All analyses were performed with the statistical software Stata, version 11.1 (Stat Corp Inc., College Station, Texas, USA). The study was approved by the ethics committee of our institute.

RESULTS

A total of 117 (90 male, 27 female) patients with a mean age of 34.10 ± 8.3 years were studied. The mean BMI was 18.07 ± 2.3 kg/m$^2$, and 70 (59.8%) patients had wasting (BMI < 18.5 kg/m$^2$). The median of baseline CD4 cell counts were 207 cells/mm$^3$ (IQR 106–284 cells/mm$^3$). This study consisted of 75 (64.1%) patients of AIDS and 42 (35.9%) non-AIDS. ART was being used by 45 (38.5%) and they were categorized to ART group and the remaining who were not using ART were categorized to ART-naïve. ART-naive group were either newly diagnosed or were those who did not fulfill the NACO criteria$^{[10]}$ for initiation of ART based on WHO clinical staging and CD4 counts.
In relation to endocrine disorders, the most common complaint was weight loss (64.9%), followed by amenorrhea (48.1% female), muscular weakness (38.5%), impotence (22% male HIV patients) [Table 1]. The wasting was evident in 59.8% of the total patients. The frequency of impotence (29.2% vs. 12%, \( P = 0.15 \)) and amenorrhea (70% vs. 35.2%, \( P = 0.12 \)) were higher in AIDS than in non-AIDS. Impotency in males (\( P = 0.16 \)) and amenorrhea in females (\( P = 0.065 \)) did not have frequent occurrence with HIV wasting [Figure 1].

Thyroid function test was done in 100 patients, of them, 9 (9%) had raised TSH; however, only 2% were overtly hypothyroid. Only 2% patients had low TSH; however, their T4 and T3 values were within normal range [Table 2].

Serum cortisol could be estimated in 97 patients. Serum cortisol values <100 nmol/l (definitive AI) was present in 5 (5.2%) patients, 38 (39.1%) patients had values >500 nmol/l (excludes AI), while 54 (55.6%) had indeterminate values, i.e., between 100–500 nmol/l [Table 2]. No patient had hypotension.

Serum testosterone, LH, and FSH could be estimated in 37 patients; all patients were males. The mean serum testosterone level was 124.81±117.61 ng/dl. Hypogonadism (serum testosterone <200 ng/dl) was found in 75.7% (28/37) patients. However, only 27% (10/37) of them had impotency on questioning. Three patients also had impotency despite their normal testosterone level. The mean LH was 2.55 ± 2.53 mIU/ml and mean FSH was 5.38 ± 3.97 mIU/ml. For male patients in whom LH and FSH was done, their values were found in normal range. BMI was related positively with serum testosterone level. But when their values were adjusted for regression analysis serum testosterone level, it was not independently related significantly to BMI [Table 3]. ART status of patients did have significant influence on the prevalence of various endocrinopathy [Table 4].

**DISCUSSION**

It is important to diagnose endocrine metabolic disorders in HIV patients. However, they still remain neglected in HIV management. The most common clinical finding is weight loss, present in 64.9% and most of them (85.52%) belonged to AIDS category. Most of the patients had normal T3 and T4 levels. TSH was raised in 9% patients (2% had overt hypothyroidism and 7% were subclinical cases). One patient had symptoms of constipation and dry skin, TSH-11 miu/ml, while other one had mild pericardial effusion and TSH of 20 miu/ml. Isolated low T4 was seen in 3% patients, and all of them were in AIDS category. Similar findings were described by Beltran et al., 2.6% patients had overt hypothyroidism, 6.6% had subclinical hypothyroidism, and 6.8% had isolated low T4.\[^{[11]}\] The prevalence of subclinical hypothyroidism in both ART naive as well as in patients who were on ART were similar; this observation is also supported by Collazos et al.\[^{[12]}\] However, in a study reported by Nelson et al.,\[^{[13]}\] a higher than expected incidence of overt hypothyroidism was found in patients receiving ART, and they recommend universal screening of subjects on therapy. Only 2% patients had low TSH,

![Figure 1: Bar diagram showing number of the patients with wasting have amenorrhea and impotency](image_url)

### Table 2: The distribution of the frequency of patients and the mean (SD) values of endocrine parameters done at the time of recruitment with respect to baseline CD4 cell counts

<table>
<thead>
<tr>
<th>Baseline CD4 counts (cells/mm³)</th>
<th>TSH (n = 100, miu/ml)</th>
<th>S. cortisol (n = 97, nmol/l)</th>
<th>S. testosterone (n = 37, ng/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;0.25</td>
<td>0.25–5.5</td>
<td>&gt;5.5</td>
</tr>
<tr>
<td>&lt;200</td>
<td>&lt;0.25</td>
<td>1</td>
<td>41</td>
</tr>
<tr>
<td>200–350</td>
<td>0</td>
<td>30</td>
<td>4</td>
</tr>
<tr>
<td>&gt;350</td>
<td>1</td>
<td>18</td>
<td>0</td>
</tr>
<tr>
<td>( P ) value</td>
<td>0.41</td>
<td>0.22</td>
<td>0.83</td>
</tr>
</tbody>
</table>
and they too were subclinical. Earlier, the prevalence of hyperthyroidism (overt and subclinical) in HIV infected patients have been reported to be <1%.[14]

We could make the diagnosis of definitive adrenal deficiency in approximately 5% patients, and around 55% patients had their serum cortisol in indeterminate range. We did not do ACTH stimulation test, therefore, the actual prevalence could not be estimated. In a study of 113 critically ill HIV infected patients, 19% prevalence of AI have been reported.[15] Whereas, in a study by Hoshino et al.,[16] cortisol levels were raised in 30.14% of patients of advanced disease as compared to 20% in patients of early stages of HIV disease. Collazos et al.[17] reported reduced serum cortisol levels in 2.8% and increased levels in 12.8% in asymptomatic HIV patients. None of these patients had symptoms of hypo- or hypercortisolism. Serum cortisol levels have shown significant relationships with the CD4 cell count and the development of cachexia.[17,18]

In the present study, a high frequency of hypogonadism was seen in males, but the serum testosterone could not be estimated in all male patients because this facility to estimate it was interrupted amid due to cost factor and unavailability of test kits. The complaint of impotency was reported more commonly in AIDS than in Non-AIDS group. In a retrospective study, Grinspoon et al. reported up to 20% prevalence of the amenorrhea. [21] This rate went up to 38% in women who were at <90% ideal body weight, clearly demonstrating an association between wasting and amenorrhea. However, we did not find significant association of amenorrhea with wasting present in HIV infected patients.

In our study, around half of the female patients had amenorrhoea. Similarly, impotency and amenorrhoea was seen more commonly in AIDS than in non-AIDS patients. In a retrospective study, Grinspoon et al. reported up to 20% prevalence of the amenorrhea. [21] This rate went up to 38% in women who were at <90% ideal body weight, clearly demonstrating an association between wasting and amenorrhea. However, we did not find significant association of amenorrhea with wasting present in HIV infected patients.

In the present study, wasting was evident in more than the half of HIV infected patients and was more frequent in the AIDS group. BMI did not correlate with either of endocrine functions tests that done here. Although controversial, hypogonadism may be more of a cause than effect of wasting. Therefore, wasting in HIV disease cannot be ascribed to be related with any endocrine disorder. There could have been the role of multiple factors acting in cohort, resulting in so-called debilitating state.

Table 3: Regression analysis showing how BMI in HIV patients was affected by hormones levels (testosterone, serum cortisol, and TSH) and CD4 counts

<table>
<thead>
<tr>
<th>Biochemical parameters</th>
<th>β Coefficient (95% CI)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSH</td>
<td>-0.14 (-0.4, 0.01)</td>
<td>0.233</td>
</tr>
<tr>
<td>Testosterone</td>
<td>0.04 (-0.5, 0.6)</td>
<td>0.864</td>
</tr>
<tr>
<td>S. Cortisol</td>
<td>0.0007 (-0.001, 0.003)</td>
<td>0.487</td>
</tr>
<tr>
<td>CD4</td>
<td>0.002 (-0.00, 0.01)</td>
<td>0.401</td>
</tr>
</tbody>
</table>

We did not have significant evidence that either of the parameters (TSH, testosterone, S. cortisol, and CD4) affect BMI.

Table 4: The distribution of the number of patients with respect to ART status for different ranges of the endocrine parameters

<table>
<thead>
<tr>
<th>ART status</th>
<th>TSH (n = 100, miu/ml)</th>
<th>Serum cortisol (n = 97, nmol/l)</th>
<th>S. testosterone (n = 37, ng/dl)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;0.25</td>
<td>0.25–5.5</td>
<td>&gt;5.5</td>
</tr>
<tr>
<td>ART</td>
<td>0</td>
<td>37</td>
<td>4</td>
</tr>
<tr>
<td>ART naïve</td>
<td>2</td>
<td>52</td>
<td>5</td>
</tr>
<tr>
<td>P value</td>
<td>0.48</td>
<td>0.93</td>
<td></td>
</tr>
</tbody>
</table>
Although our results are limited by factors such as small sample size, unequal frequency of patients between AIDS and Non-AIDS group, and likewise between ART and ART-naïve patients, and that stipulated hormonal assay could not be performed and measured in all patients, we would like to conclude that hypothyroidism seen in HIV patients was predominantly subclinical. Decreased levels of serum cortisol were found, although with unclear clinical significance. Male patients had hypogonadism, probably hypogonadotropic type, but the frequency of symptoms of impotency did not match with the frequency of hypogonadism detected on hormonal assay. Authors recommend that a large study from this part of world is required to better elucidate the endocrine disorders in HIV infected patients and their relation with stages of the HIV infection and ART being taken.

ACKNOWLEDGEMENT

The authors wish to express their deepest gratitude and warmest appreciation to all HIV patients enrolled in this study, who, in any way have contributed and inspired the authors for the overall success of the undertaking.

REFERENCES


How to cite this Article:

Source of Support: Nil, Conflict of Interest: None declared.
Date of Acceptance: January 12, 2013

Jain, et al.: Endocrine dysfunctions in HIV infection